Portal de Periódicos da CAPES

Development of Parvifloron D-Loaded Smart Nanoparticles to Target Pancreatic Cancer

2018; Multidisciplinary Digital Publishing Institute; Volume: 10; Issue: 4 Linguagem: Inglês

10.3390/pharmaceutics10040216

1999-4923

Ana Santos-Rebelo, Catarina García, Carla Eleutério, Ana Bastos, Sílvia Castro Coelho, Manuel A. N. Coelho, Jesús Molpeceres, Ana S. Viana, Lia Ascensão, João F. Pinto, Maria Manuela Gaspar, Patrícia Rijo, Catarina Pinto Reis,

Enhanced Oil Recovery Techniques

Pancreatic cancer is the eighth leading cause of cancer death worldwide. For this reason, the development of more effective therapies is a major concern for the scientific community. Accordingly, plants belonging to Plectranthus genus and their isolated compounds, such as Parvifloron D, were found to have cytotoxic and antiproliferative activities. However, Parvifloron D is a very low water-soluble compound. Thus, nanotechnology can be a promising delivery system to enhance drug solubility and targeted delivery. The extraction of Parvifloron D from P.ecklonii was optimized through an acetone ultrasound-assisted method and isolated by Flash-Dry Column Chromatography. Then, its antiproliferative effect was selectivity evaluated against different tumor cell lines (IC50 of 0.15 ± 0.05 μM, 11.9 ± 0.7 μM, 21.6 ± 0.5, 34.3 ± 4.1 μM, 35.1 ± 2.2 μM and 32.1 ± 4.3 μM for BxPC3, PANC-1, Ins1-E, MCF-7, HaCat and Caco-2, respectively). To obtain an optimized stable Parvifloron D pharmaceutical dosage form, albumin nanoparticles were produced through a desolvation method (yield of encapsulation of 91.2%) and characterized in terms of size (165 nm; PI 0.11), zeta potential (-7.88 mV) and morphology. In conclusion, Parvifloron D can be efficiently obtained from P.ecklonii and it has shown selective cytotoxicity to pancreatic cell lines. Parvifloron D nanoencapsulation can be considered as a possible efficient alternative approach in the treatment of pancreatic cancer.